Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application.
Drug Deliv
; 29(1): 2296-2319, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2187331
ABSTRACT
The emerging cell membrane (CM)-camouflaged poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) (CM@PLGA NPs) have witnessed tremendous developments since coming to the limelight. Donning a novel membrane coat on traditional PLGA carriers enables combining the strengths of PLGA with cell-like behavior, including inherently interacting with the surrounding environment. Thereby, the in vivo defects of PLGA (such as drug leakage and poor specific distribution) can be overcome, its therapeutic potential can be amplified, and additional novel functions beyond drug delivery can be conferred. To elucidate the development and promote the clinical transformation of CM@PLGA NPs, the commonly used anucleate and eukaryotic CMs have been described first. Then, CM engineering strategies, such as genetic and nongenetic engineering methods and hybrid membrane technology, have been discussed. The reviewed CM engineering technologies are expected to enrich the functions of CM@PLGA for diverse therapeutic purposes. Third, this article highlights the therapeutic and diagnostic applications and action mechanisms of PLGA biomimetic systems for cancer, cardiovascular diseases, virus infection, and eye diseases. Finally, future expectations and challenges are spotlighted in the concept of translational medicine.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biomimetics
/
Nanoparticles
Type of study:
Prognostic study
Language:
English
Journal:
Drug Deliv
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
10717544.2022.2100010
Similar
MEDLINE
...
LILACS
LIS